Current Takeaway
Immune dysregulation remains one of the most consistent findings across ME/CFS and Long COVID, but the newer evidence suggests that it is not just a generic “inflammation” signal. The pattern increasingly looks like a mix of chronic antigen-driven adaptive dysfunction, persistent innate activation, and abnormal immune-tissue signaling that may differ by subgroup and trigger history.
The latest additions sharpen that picture. New work tracks exhausted or clonally expanded T cells back toward specific unresolved antigens, maps monocyte, B-cell, T-cell, and NK-cell abnormalities at single-cell resolution, identifies elevated IL-11 and MMP-9 with EBV-responsive mast-cell signaling, and adds glycosylation changes in serum, IgG, and red blood cells that could affect both immune function and blood flow. These findings fit the idea that immune dysfunction is interacting with vascular and metabolic systems rather than operating in isolation.
The evidence still needs cautious handling. Some of the newest material is preliminary, including a webinar on antigen discovery, a single-cell preprint, and a thesis-based glycosylation study. Even the peer-reviewed additions remain mostly cross-sectional, so they help define plausible mechanisms and subgroups more than they prove one dominant cause.
Why This Matters
Unraveling the precise mechanisms of immune dysregulation is essential for moving post-infectious conditions from heterogeneous clinical diagnoses to stratified, biologically targeted therapeutics. Mapping these pathways provides a cellular explanation for hallmark symptoms like post-exertional malaise, brain fog, and sensory hypersensitivity, linking them directly to pro-inflammatory cytokine cascades, impaired regional blood perfusion driven by endothelial senescence, and neurovascular inflammation. Furthermore, identifying distinct immunophenotypic signatures—such as monocyte polarization differences and T-cell receptor clusters—enables the classification of patients into specific physiological subgroups. This biological stratification replaces trial-and-error treatment regimens with precision medicine, enabling clinical trials to test targeted interventions like selective immunomodulators, mast cell stabilizers, or hormone therapies on the patient subgroups most likely to respond.
State of Evidence
- Established: Post-infectious immune abnormalities are repeatedly observed in both ME/CFS and Long COVID, including altered lymphocyte populations, impaired cytotoxic-cell function, inflammatory cytokine changes, and evidence of ongoing innate-adaptive mismatch.
- Plausible but early: Antigen-specific T-cell exhaustion, monocyte and NK-cell inflammatory programs, mast-cell-linked IL-11/MMP-9 signaling, and altered glycosylation patterns all have growing support as subgroup-defining mechanisms. These may help explain why some patients look more immune-activated, others more immune-suppressed, and some show stronger vascular or autonomic overlap.
- Not established: It is still not clear which immune abnormalities are upstream disease drivers, which are downstream consequences, and which are compensatory responses. Antigen-discovery work has not yet produced validated public antigen targets, and immune-glycan abnormalities are not ready for clinical classification.
- Key limitations: Several important 2026 additions are preliminary, preprint, or thesis-based. Most studies remain cross-sectional and blood-based, which limits conclusions about tissue-resident immune dysfunction in the gut, marrow, vasculature, or nervous system.
Timeline
2023-12-27 - Intracellular cytokine staining identifies CD8+ T-cell dysfunction in ME/CFS and Long COVID
CD8+ T cells from both ME/CFS and Long COVID patients were shown to have a significantly diminished capacity to produce interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) after stimulation. A small retrospective case series (n = 8) showed that treatment with a nebulized antioxidant/anti-pathogen agent (Inspiritol) was associated with improved CD8+ T-cell function and a 54% decrease in symptom severity. This identifies CD8+ T-cell dysfunction (resembling T-cell exhaustion in chronic viral infections) as a shared immunological biomarker, suggesting that impaired host defense against latent pathogens is a common pathomechanism. However, the small size and retrospective, uncontrolled nature of the case series means the therapeutic efficacy of the nebulized agent is not established and requires validation in randomized controlled trials.
Sources:
2024-02-21 - Landmark NIH deep-phenotyping study links post-infectious ME/CFS to chronic immune activation and neuro-immune dysfunction
An intensive, multi-disciplinary inpatient study of post-infectious ME/CFS (n = 17) identified chronic immune activation (altered B-cell subsets), autonomic dysfunction (low heart rate variability), and metabolic alterations. The study linked these peripheral changes to central neurovascular coupling defects and a dysfunction in the right temporoparietal junction affecting effort preference. This deep phenotyping provides a unified biological framework showing that ME/CFS is a multi-system physical illness rooted in immune-mediated brain dysfunction rather than a psychological condition. However, due to the small sample size and strict exclusion criteria (excluding severe, non-ambulatory patients), these findings may not generalize across the broader, heterogeneous ME/CFS patient population.
Sources:
2024-04-08 - Longitudinal N-of-1 profiling of severe ME/CFS associates symptom severity with Th2-type cytokine profiles
A four-year longitudinal study of an extremely severe, bedridden ME/CFS patient integrated multiplex cytokine profiling across nine blood samples with clinical and medication logs. The analysis showed that marginal symptom improvements (especially in cognitive function and sensory overload) correlated with a reduction in Th2-type cytokines and decreased activity of mast cells and eosinophils. This provides longitudinal evidence that a Th2-dominant immune profile and mast cell/eosinophil activation are associated with severe ME/CFS symptoms, strengthening the pathobiological link to hypermobility spectrum disorders (HSD) and mast cell activation syndrome (MCAS). However, being a single-patient (N-of-1) study, these immunopathological correlations cannot be assumed to represent the mechanisms driving milder cases or the wider patient population.
Sources:
2024-10-22 - Transcriptional profiling distinguishes immune suppression in ME/CFS from hyper-activation in Long COVID
PBMC gene expression analysis using an immune exhaustion panel in ME/CFS (n = 14) and Long COVID (n = 15) patients revealed distinct transcriptional signatures. ME/CFS was characterized by immune suppression (downregulated interferon signaling and immunoglobulin genes), whereas Long COVID exhibited immune hyper-activation and antigen presentation dysregulation. The study shows that despite presenting with highly overlapping clinical symptoms and physical disability, post-infectious ME/CFS and Long COVID involve divergent post-infectious immunopathologies. However, the small sample sizes prevent stratification by clinical sub-phenotypes, and these transcriptional profiles require validation in larger, longitudinal cohorts.
Sources:
2025-09-08 - Persistent NLRP3 inflammasome activation correlates with neuropsychiatric and fatigue symptoms in Long COVID
Serum analysis of 161 Long COVID patients assessed 6 to 9 months post-infection demonstrated that levels of NLRP3, caspase-1, IL-1β, and IL-18 were significantly elevated in patients who experienced severe acute illness. These elevated inflammasome markers correlated strongly with chronic fatigue and neuropsychiatric symptom severity, with acute oxygen desaturation () serving as a strong predictor of chronic NLRP3 activity. This identifies the NLRP3 inflammasome pathway as a persistent driver of systemic inflammation in Long COVID, providing a rational target for clinical trials evaluating NLRP3 inhibitors. However, the observational, case-control design cannot establish a causal link showing that NLRP3 activation directly drives neuropsychiatric symptoms, and replication in independent cohorts is needed.
Sources:
2025-10-24 - Computational model links ME/CFS susceptibility HLA alleles to weak binding of post-viral pathogens
An in silico binding study of HLA alleles associated with ME/CFS risk (C07:04 and DQB103:03) and protection (B08:01 and DPB102:01) demonstrated that risk alleles bind herpesvirus (HHV), SARS-CoV-2, and Borrelia burgdorferi proteins with significantly weaker affinity compared to protective alleles. This provides a potential immunogenetic explanation for post-infectious syndromes, suggesting that an inadequate HLA makeup leads to poor antigen clearance, persistent viral/bacterial presence, and chronic immune activation. However, these in silico predictions require biological validation in live patient cohorts to confirm that weak HLA binding corresponds to antigen persistence in tissues.
Sources:
2025-11-07 - Retrospective cohort study establishes mast cell activation as a frequent and treatable comorbidity in ME/CFS
Analysis of a self-reported cohort (n = 687) and a retrospective clinical cohort (n = 383) showed that up to 25.3% of ME/CFS patients met the criteria for clinically relevant mast cell activation (MCA). MCA involvement was strongly associated with a higher prevalence of orthostatic intolerance (OI) and POTS, and patients with both MCA and OI reported significant symptom improvement from mast-cell targeted treatments. This provides a clinical rationale for screening ME/CFS patients for mast cell activation to guide personalized therapy, establishing that MCA-targeted drugs can alleviate severe autonomic symptoms in this patient subset. However, the reliance on retrospective clinical records and self-reported surveys introduces potential biases, and double-blind, placebo-controlled trials are required to validate treatment efficacy.
Sources:
2025-11-18 - Multi-omics profiling identifies profound sex-specific immune and endocrine dysregulation in Long COVID
Integrated flow cytometric, cytokine, and transcriptomic profiling of 78 Long COVID patients meeting ME/CFS criteria (58 female, 20 male) identified distinct immunopathological signatures between the sexes. Females exhibited a myelopoiesis shift (increased neutrophils/monocytes, reduced lymphocytes, and Treg depletion) and upregulated neuroinflammatory genes correlating with brain fog, alongside low testosterone and elevated gut leakiness markers; males showed less inflammation and stress-response transcriptomic signatures. This explains the female-biased prevalence of these syndromes, showing that sex-specific hormonal profiles (low testosterone in females, low estradiol in males, and low cortisol in both) correlate with distinct immune dysregulation patterns. However, the cross-sectional design cannot determine if hormonal deficiencies are the cause or consequence of chronic inflammation, and hormone replacement therapy requires clinical validation.
Sources:
2025-11-20 - Single-cell epigenomics reveals NF-κB priming in a distinct monocyte subset driving post-exertional inflammation
Single-cell chromatin accessibility (scATAC-seq) and transcriptomic profiling at baseline and during post-exertional malaise (PEM) identified a unique subpopulation of classical monocytes characterized by reduced CD14 expression and epigenetic priming near pro-inflammatory genes, driven by NF-κB transcription factor activation. This demonstrates that PEM is driven by a persistent state of monocyte activation etched into the cells’ epigenome, explaining the acute inflammatory reaction to physical exertion. However, it remains unclear if these epigenetic alterations are reversible or what initial signaling events establish this persistent chromatin remodeling.
Sources:
2025-11-25 - Mechanistic review outlines mTOR hyperactivation axis linking infections to neuroinflammation
A multidisciplinary review proposed a three-step pathogenetic model of post-infectious neuroinflammation driven by sustained mTOR activation, where mTOR first promotes B-cell/T-cell autoimmunity, then weakens the blood-brain barrier, and finally activates microglia to disrupt synaptic maintenance. This provides a molecular link between peripheral infection and central nervous system symptoms, establishing a scientific basis for clinical trials investigating mTOR inhibitors like rapamycin. However, the review synthesized preclinical and indirect clinical literature; direct measurement of tissue-level mTOR activation in post-infectious patient cohorts is still required.
Sources:
2025-12-05 - Large-scale cohort study confirms persistent CD8+ T-cell depletion 20 months post-COVID-19
A retrospective cohort study of 40,537 individuals demonstrated that a single mass infection wave led to a persistent reduction in lymphocyte subsets. Even 20 months post-infection, CD8+ T cells remained 9.9% below baseline, and patients with pre-existing cardiovascular disease showed a 72.9% reduction in total T cells with minimal recovery. This provides high-volume clinical evidence that SARS-CoV-2 can induce long-lasting immune compromise, particularly affecting cytotoxic T cells, which may drive chronic post-viral fatigue and compromise latent pathogen control. However, the study analyzed hospital-visiting patients, which may introduce selection bias, and does not determine if these lymphocyte drops represent permanent damage or a prolonged recovery phase.
Sources:
2025-12-08 - Comparative analysis reveals identical lymphocyte and cytokine profiles in ME/CFS and Long COVID
A cross-sectional comparative study (190 participants: 65 ME/CFS, 54 Long COVID, 70 controls) demonstrated that both patient cohorts exhibit nearly identical general immune profiles. Both groups showed significantly depleted total lymphocytes, CD8+ T cells, and NK cells, alongside elevated pro-inflammatory (IL-6, TNF) and regulatory (IL-4, IL-10) cytokines. This supports the hypothesis of a shared immunopathological basis for both conditions, indicating that clinical and research progress in one field will likely translate to the other. However, while general lymphocyte and cytokine changes overlap, this cross-sectional study did not examine cell-specific functional regulation or tissue-resident immune cells.
Sources:
2025-12-10 - Cytotoxic cell immunosenescence and activation signatures differentiate ME/CFS severity subgroups
Flow cytometric profiling of cytotoxic cells in 96 ME/CFS patients categorized by severity showed that mild/moderate cases are characterized by early immunosenescence (CD28-CD57- cells, suggesting chronic response to persistent viral antigens), while severe cases exhibit high levels of activated CD8+ T cells and elevated pro-inflammatory cytokine production. This shows that ME/CFS involves distinct immunological stages or mechanisms depending on disease severity, suggesting a shift from viral-focused immune responses to non-specific chronic inflammation as disability worsens. However, the study lacks longitudinal tracking to prove that patients transition from an immunosenescent phenotype to a hyper-activated inflammatory state as severity increases.
Sources:
2025-12-12 - Multi-omics analysis detects persistent JAK-STAT pathway activation in Long COVID
Multi-omic analysis of 142 individuals (with independent validation) demonstrated that Long COVID patients exhibit persistent activation of the IL-6 and JAK-STAT signaling pathways and T-cell exhaustion beyond 180 days post-infection, independently of active viral replication in plasma. This identifies the JAK-STAT pathway as a primary metabolic regulator of chronic inflammation in Long COVID, suggesting that JAK inhibitors could serve as targeted treatments. However, the study does not establish if JAK-STAT activation is driven by low-level viral persistence in tissues (hidden reservoirs) or a self-sustaining autoimmune loop.
Sources:
2026-01-09 - Endothelial senescence framework links immune clearance failure to chronic tissue perfusion deficits
A theoretical model proposed that virus-induced endothelial senescence (“zombie cells”) is a primary driver of ME/CFS and Long COVID. In this model, impaired immune clearance allows senescent cells to persist and release SASP factors, promoting microvascular clotting and restricting regional blood flow. This provides a mechanistic bridge connecting cellular immune dysfunction (impaired NK and CD8+ T cell cytotoxicity) to vascular perfusion deficits, explaining symptoms like post-exertional malaise and brain fog. However, as a theoretical framework, this model requires empirical validation in clinical cohorts using specific senescent endothelial cell biomarkers.
Sources:
2026-02-02 - Sleep disturbance in Long COVID associated with impaired lipid-mediated inflammatory resolution
Mass spectrometry analysis of 31 Long COVID patients and 8 controls showed that severe sleep disturbance correlates with significantly depleted levels of specialized pro-resolving mediators (SPMs like 17-HDHA and Resolvin D1) and elevated PGE2. This demonstrates that sleep disruption impairs the body’s active physiological mechanisms for resolving inflammation, suggesting sleep quality as a critical therapeutic target. However, the small, observational study cannot establish a direct causal path determining whether sleep disruption causes SPM depletion or if chronic inflammation disrupts sleep pathways.
Sources:
2026-02-23 - Plasma proteomic profiling reveals stable, spike-protein-independent inflammatory state in late PASC
Plasma proteomic profiling of 92 PASC patients at 34 months post-infection identified 26 differentially expressed proteins, with Oncostatin M (OSM) and IL-1 receptor antagonist (IL1RN) being most significantly upregulated, in the absence of detectable plasma spike protein. This shows that PASC involves a stable, low-grade inflammatory state that persists for years independently of detectable viral antigen replication in the blood, pointing toward a “locked” immune state. However, it does not rule out the presence of viral antigens in deep tissues (sanctuary sites) or identify the primary trigger maintaining this inflammatory memory.
Sources:
2026-02-25 - Single-cell RNA sequencing maps Galectin-9–TIM-3-driven T-cell depletion in Long COVID
Single-cell RNA sequencing 12 months post-infection showed significant depletion of naive T cells, Tregs, MAIT, and γδ T cells, alongside impaired NK cell cytotoxicity and pro-inflammatory monocyte skewing. The study identified the Galectin-9–TIM-3 interaction as a major driver of this T-cell depletion, which was less pronounced in idiopathic ME/CFS. This maps a specific molecular pathway of immune remodeling and exhaustion, validating the biological reality of Long COVID and providing a potential diagnostic biomarker and therapeutic target. However, the study was limited to a small, female-only cohort, and these immune remodeling patterns need validation in male cohorts.
Sources:
2026-03-01 - Innate immune review highlights persistent macrophage activation and failed resolution in PASC
A review of human cohorts and humanized mouse models synthesized evidence that lung-resident macrophages harbor viral RNA and maintain active inflammasomes, leading to chronic release of IL-1 and IL-18, driven by sustained interferon and IgG-mediated antibody-dependent enhancement. This highlights macrophage activation and failed innate resolution as central to PASC, demonstrating that inhibiting the NLRP3 inflammasome can reverse tissue pathology in preclinical models. However, inhibiting the NLRP3 inflammasome in models also triggered the release of infectious virus, indicating a potential risk that must be evaluated in human trials.
Sources:
2026-03-06 - Narrative review links mast cell activation to neuropathic pain and sensory nerve damage in Long COVID
A synthesis of preclinical and clinical data proposed that SARS-CoV-2 spike protein triggers mast cells via ACE2 and TLR4 to release neurotoxic tryptase and IL-6, which sensitizes peripheral sensory nerves and impairs the blood-brain barrier. This provides a mechanistic explanation for small-fiber neuropathy and neuropathic pain in Long COVID and ME/CFS, supporting the clinical use of flavonoids and antihistamines. However, direct clinical evidence showing that mast cell stabilizers or antihistamines can reverse sensory nerve damage in patients is still lacking.
Sources:
2026-04-12 - Flow cytometry demonstrates divergent monocyte and dendritic cell pathophysiology in ME/CFS and Long COVID
Flow cytometric profiling of 207 participants showed that Long COVID is associated with increased M2-like monocyte polarization and dendritic cell expansion (indicating chronic activation/exhaustion), whereas ME/CFS is characterized by reduced costimulatory molecules and impaired CCR7-mediated immune cell trafficking (indicating immune suppression). This confirms that despite overlapping clinical presentations, ME/CFS and Long COVID are immunologically divergent diseases, requiring distinct therapeutic strategies. However, as a preprint, these findings require peer-reviewed validation and confirmation in independent patient cohorts.
Sources:
2026-04-28 - Antigen-discovery project targets the proteins driving dysfunctional T cells
In a Solve ME/CFS Initiative webinar, Liisa Selin, Ayano Kohlgruber, and Roshan Kumar outlined an ongoing antigen-discovery study focused on exhausted and clonally expanded T cells in ME/CFS and Long COVID. Their approach combines prior evidence of reduced perforin and reduced IFN-gamma and TNF-alpha production with single-cell T-cell receptor analysis, then tests those receptors against HLA-displayed libraries of microbial and human peptides. This matters because it moves the field from describing exhausted T cells toward asking what they are actually recognizing, including the possibility of persistent pathogen antigens, molecular mimicry, or both. If the approach works, it could eventually define biologically meaningful subgroups rather than treating all immune dysfunction as nonspecific inflammation. At this stage, though, it is still an active project presentation without validated antigen hits or published cohort-scale confirmation.
Sources:
2026-05-05 - T-cell receptor sequencing project targets specific antigens driving CD8+ T-cell exhaustion
A Solve M.E. Catalyst-funded project utilized single-cell immune profiling and T-cell receptor (TCR) sequencing to map TCR clusters of exhausted CD8+ T cells against human leukocyte antigen (HLA)–displayed microbial and human self-proteins. This project aims to identify the specific pathogens (e.g. herpesviruses, SARS-CoV-2, Borrelia) or self-proteins driving chronic T-cell exhaustion, which will enable precise diagnostic profiling and patient stratification. However, the project is actively mapping these targets, and validated diagnostic subsets have not yet been established.
Sources:
2026-05-08 - MIRACLE study identifies reduced mtDNA copy numbers and altered HDL function in ME/CFS
The multi-center MIRACLE study (200 patients, including severely ill bedridden patients, and 200 controls) demonstrated significantly lower mitochondrial DNA (mtDNA) copy numbers (indicating reduced mitochondrial density) and partially reduced inflammatory potential of HDL. This links systemic energy production failure (mitochondrial depletion) and lipidome alterations to the clinical presentation of ME/CFS, validating metabolic stress in the full spectrum of disease severity. However, the study does not establish the causal order between mitochondrial depletion, HDL alterations, and systemic immune dysregulation.
Sources:
2026-06-05 - Clinical and in vitro study associates elevated IL-11 and MMP-9 with EBV-induced mast cell activation
Serum measurements showed significantly elevated IL-11 and MMP-9 in ME/CFS patients compared to healthy controls, and an in vitro model demonstrated that recombinant Epstein-Barr Virus (rEBV) protein stimulates mast cells to release MMP-9. This identifies a potential viral-trigger pathway where EBV proteins stimulate mast cell release of MMP-9, a tissue-remodeling enzyme capable of disrupting the blood-brain barrier and promoting localized neuroinflammation. However, the clinical generalizability is limited by small sample sizes, and the direct pathogenetic role of IL-11 and MMP-9 in blood-brain barrier permeability needs to be demonstrated in vivo.
Sources:
2026-06-08 - Single-cell RNA sequencing maps coordinated B-cell, monocyte, T-cell, and NK-cell dysregulation in Long COVID
Satpathy and colleagues analyzed 156,478 peripheral blood mononuclear cells from 20 Long COVID patients and 18 recovered controls using single-cell RNA sequencing. They found evidence of sustained antigen-exposed B-cell states, interferon-high and migratory monocyte programs, exhausted effector-memory T-cell signatures, and NK-cell abnormalities that varied with clinical severity. In the more severe group, AP-1-driven inflammatory signaling in CD14-positive monocytes and NK cells stood out as a plausible organizing pathway. This is useful because it shows multiple immune compartments moving together rather than one isolated abnormal cell type. It is still a small preprint restricted to peripheral blood, so the results need peer review and confirmation in broader cohorts.
Sources:
2026-06-28 - Glycosylation study suggests immune and red-blood-cell desialylation changes in ME/CFS and Long COVID
A comparative cohort study from TU Wien found higher free serum sialic acid in symptomatic ME/CFS and Long COVID groups, altered IgG N-glycan patterns, and reduced lectin-based hemagglutination in ME/CFS red blood cells consistent with surface desialylation. These findings matter because glycosylation affects antibody behavior, cell-cell signaling, and the electrical and mechanical properties of red blood cells, so the result could help connect immune dysregulation to vascular symptoms. The study also reported overrepresentation of blood type A in the ME/CFS cohort, which is interesting as a susceptibility clue but remains preliminary. This is still an early cohort study with a small ME/CFS sample, so it should be treated as a lead rather than a settled biomarker framework.
Sources:
Open Questions
- What molecular mechanisms drive the divergence between the immune hyper-activation/exhaustion state in Long COVID and the immune suppression/trafficking deficit state in ME/CFS?
- How does the epigenetic priming (NF-κB activation) observed in classical monocytes interact with physical exertion to trigger the onset and severity of post-exertional malaise?
- What are the precise viral or autoimmune target antigens recognized by exhausted CD8+ T-cell receptors in ME/CFS and Long COVID cohorts, and can they be used to stratify patients for targeted antivirals or immunotherapies?
- What is the clinical safety and efficacy profile of specialized pro-resolving mediators (SPMs) or JAK-STAT inhibitors when evaluated in double-blind, placebo-controlled trials for post-viral syndromes?
- Can therapeutic regulation of sex hormones (such as testosterone in females and estradiol in males) or low-dose cortisol safely restore immune homeostasis and resolve myelopoietic shifts?